Medindia

X

InteRNA Technologies Announces Establishment of Scientific Advisory Board

Thursday, July 8, 2010 General News J E 4
Advertisement
UTRECHT, the Netherlands, July 8, 2010 InteRNATechnologies B.V., a biopharmaceutical company focusing on the development ofintelligent microRNA (miRNA)-based therapeutics for cancer, announces theestablishment of its Scientific Advisory Board (SAB). The SAB will furtherguide the Company in the development of cancer therapies based on the uniquefunctions of its proprietary miRNAs.

The SAB is chaired by Emile E. Voest, MD, PhD, Professor of MedicalOncology at the Department of Medical Oncology, UMC Utrecht, the Netherlands.

"We are very pleased with the formation of our SAB and feel honored tocollaborate with this experienced team that is highly committed advising theCompany on moving forward its research and development towards the clinic",said Roel Schaapveld, CEO of InteRNA Technologies. "The complementaryknowledge of the renowned clinicians and scientists in this team will play asignificant role in our R&D programs and success of the Company."

Edwin Cuppen, scientific co-founder of InteRNA Technologies, commented:"While fundamental research has now unequivocally demonstrated the importanceof miRNA's in regulation and deregulation of biological processes, InteRNATechnologies has in the past few years build up a unique position inconverting this knowledge into miRNA-based cancer treatment strategies. Theseactivities are now further supported by a wealth of knowledge and expertisethrough this SAB, which will undoubtedly further accelerate the path towardsmiRNA-based drugs."

About InteRNA Technologies B.V.

InteRNA Technologies B.V. actively explores and exploits opportunities totranslate its unique collection of miRNAs and miRNA discovery and validationtechnologies into successful diagnostic, prognostic and therapeuticapplications. The company's primary focus is to unravel the role of itsproprietary miRNAs in cancer.

InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund andhas established close relationships with the research groups of its foundersEdwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute(Utrecht, the Netherlands), leading scientific groups in the field of miRNAresearch.

See for more information http://www.interna-technologies.com.Other distinguished members are: - Jaap Verweij, MD, PhD, Professor of Medical Oncology at the Department. of Medical Oncology at Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; - William C. Hahn, MD, PhD, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute and Senior Associate Member at the Broad Institute of Harvard and MIT, Boston, USA; - Allan Balmain, PhD, FRSE, Barbara Bass Bakar Distinguished Professor in Cancer Genetics at UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA; - Graham Dixon, PhD, Sr. VP Drug Discovery, Galapagos NV, Mechelen, Belgium; - Edwin Cuppen, PhD, scientific co-founder of InteRNA Technologies, and Professor of Genome Biology at Utrecht University, Professor of Human Genetics and head of the Research section of the Department of Medical Genetics, UMC Utrecht and staff scientist at Hubrecht Institute, Utrecht, the Netherlands; - Eugene Berezikov, PhD, scientific co-founder of InteRNA Technologies and staff scientist at Hubrecht Institute, the Netherlands.

SOURCE InteRNA Technologies B.V.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Bayer HealthCare Presents Phase I Clinical Data fo...
S
NxStage to Report Second Quarter Fiscal 2010 Finan...